BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15255540)

  • 21. Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2014; 15(21):9335-9. PubMed ID: 25422221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.
    Ghossein RA; Scher HI; Gerald WL; Kelly WK; Curley T; Amsterdam A; Zhang ZF; Rosai J
    J Clin Oncol; 1995 May; 13(5):1195-200. PubMed ID: 7537803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.
    Katz AE; Olsson CA; Raffo AJ; Cama C; Perlman H; Seaman E; O'Toole KM; McMahon D; Benson MC; Buttyan R
    Urology; 1994 Jun; 43(6):765-75. PubMed ID: 7515202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
    Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
    Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
    Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
    Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
    Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
    J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
    Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
    Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy.
    de Cremoux P; Ravery V; Podgorniak MP; Chevillard S; Toublanc M; Thiounn N; Tatoud R; Delmas V; Calvo T; Boccon-Gibod L
    Eur Urol; 1997; 32(1):69-74. PubMed ID: 9266235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
    Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
    Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse transcriptase-polymerase chain reaction assays for prostate cancer.
    Olsson CA; de Vries GM; Buttyan R; Katz AE
    Urol Clin North Am; 1997 May; 24(2):367-78. PubMed ID: 9126234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
    Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
    Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival.
    Doyen J; Alix-Panabières C; Hofman P; Parks SK; Chamorey E; Naman H; Hannoun-Lévi JM
    Crit Rev Oncol Hematol; 2012 Mar; 81(3):241-56. PubMed ID: 21680196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
    Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
    Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.